| Project/Area Number |
16K15767
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Emergency medicine
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
HORI Satoshi
IHARA Shingo
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | アミノレブリン酸 / サイトカイン / 抗炎症効果 / 5-アミノレブリン酸 / 敗血症 / 虚血再灌流傷害 / 抗炎症作用 |
|---|
| Outline of Final Research Achievements |
5-aminolevulinic acid (ALA) is a synthetic precursor of heme, which is degraded by heme oxygenase-1 (HO-1). Recent studies reported that 5-ALA induced the up-regulation of HO-1 mRNA. HO-1 is an isoform of heme oxygenase that catabolizes cellular heme to bilverdin, carbon monoxide, and free iron. This study demonstrated that treatment with 5-ALA marked reduction of cytokine IL-6 production. HO-1 is well-known to be induced not only by its substrate, but also by various stresses such as sepsis. We suggest that HO-1 expression could prevent the development of an inflammatory response such as sepsis. However, few reports have been presented on the mechanism of HO-1 induction by 5-ALA. 5-ALA could act in a protective manner in the inflammatory process and reduce cytokines which contribute to the development of multiple organ dysfunction and a poor outcome.
|
